Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting Sep 15, 2022
Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma Sep 1, 2022
Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update Aug 30, 2022
Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering Aug 25, 2022
Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering Aug 18, 2022
Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering Aug 4, 2022
Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia Aug 1, 2022
Navidea Biopharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record for the Previously Announced Rights Offering Aug 1, 2022
